
Nicole Concin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7082873/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 12-39.	2.5	859
2	ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology, 2019, 30, 672-705.	1.2	665
3	Clinical Relevance of E2F Family Members in Ovarian Cancer—An Evaluation in a Training Set of 77 Patients. Clinical Cancer Research, 2007, 13, 144-151.	7.0	103
4	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 153-190.	2.8	99
5	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiotherapy and Oncology, 2021, 154, 327-353.	0.6	96
6	Clinical Relevance of Dominant-Negative p73 Isoforms for Responsiveness to Chemotherapy and Survival in Ovarian Cancer: Evidence for a Crucial p53-p73 Cross-talk In vivo. Clinical Cancer Research, 2005, 11, 8372-8383.	7.0	89
7	Mineral oil in human tissues, Part I: Concentrations and molecular mass distributions. Food and Chemical Toxicology, 2014, 72, 312-321.	3.6	77
8	BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). European Journal of Cancer, 2014, 50, 2090-2098.	2.8	75
9	Mineral oil paraffins in human body fat and milk. Food and Chemical Toxicology, 2008, 46, 544-552.	3.6	72
10	Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer. BMC Cancer, 2016, 16, 102.	2.6	68
11	Recommended Guidelines for Validation, Quality Control, and Reporting of <i>TP53</i> Variants in Clinical Practice. Cancer Research, 2017, 77, 1250-1260.	0.9	68
12	Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. International Journal of Gynecological Cancer, 2020, 30, 436-440.	2.5	61
13	Uterine serous carcinoma. Gynecologic Oncology, 2021, 162, 226-234.	1.4	58
14	ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. International Journal of Gynecological Cancer, 2021, 31, 961-982.	2.5	54
15	Mineral oil in human tissues, Part II: Characterization of the accumulated hydrocarbons by comprehensive two-dimensional gas chromatography. Science of the Total Environment, 2015, 506-507, 644-655.	8.0	50
16	ESGO–SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers. Lancet Oncology, The, 2020, 21, e360-e368.	10.7	50
17	The genetic landscape of 87 ovarian germ cell tumors. Gynecologic Oncology, 2018, 151, 61-68.	1.4	44
18	Use of Underarm Cosmetic Products in Relation to Risk of Breast Cancer: A Case-Control Study. EBioMedicine, 2017, 21, 79-85.	6.1	43

NICOLE CONCIN

#	Article	IF	CITATIONS
19	<scp>ESGO</scp> / <scp>ISUOG</scp> / <scp>IOTA</scp> / <scp>ESGE</scp> Consensus Statement on preoperative diagnosis of ovarian tumors. Ultrasound in Obstetrics and Gynecology, 2021, 58, 148-168.	1.7	42
20	Prognostic Relevance of Pretherapeutic Gamma-Glutamyltransferase in Patients with Primary Metastatic Breast Cancer. PLoS ONE, 2015, 10, e0125317.	2.5	40
21	Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene, 2011, 30, 4038-4049.	5.9	39
22	E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer. Cancer Research, 2010, 70, 4613-4623.	0.9	32
23	Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. Gynecologic Oncology, 2020, 156, 308-314.	1.4	32
24	Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs. Cell Death and Differentiation, 2014, 21, 1240-1249.	11.2	29
25	Evidence for Cosmetics as a Source of Mineral Oil Contamination in Women. Journal of Women's Health, 2011, 20, 1713-1719.	3.3	27
26	Combining conventional therapy with immunotherapy: AÂrisky business?. European Journal of Cancer, 2019, 113, 41-44.	2.8	25
27	The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study. Tumor Biology, 2016, 37, 3009-3016.	1.8	23
28	Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium. Frontiers in Oncology, 2019, 9, 832.	2.8	23
29	Clear cell carcinoma of the endometrium. Gynecologic Oncology, 2022, 164, 658-666.	1.4	23
30	HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium. OncoTargets and Therapy, 2014, 7, 1563.	2.0	18
31	Polymer-Ligand-Based ELISA for Robust, High-Throughput, Quantitative Detection of p53 Aggregates. Analytical Chemistry, 2018, 90, 13273-13279.	6.5	18
32	Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. Cell Death and Differentiation, 2017, 24, 300-316.	11.2	16
33	Jump in the fire — heat shock proteins and their impact on ovarian cancer therapy. Critical Reviews in Oncology/Hematology, 2016, 97, 152-156.	4.4	15
34	Fetal weight estimation at term – ultrasound versus clinical examination with Leopold's manoeuvres: a prospective blinded observational study. BMC Pregnancy and Childbirth, 2019, 19, 122.	2.4	15
35	European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 1508-1529.	2.5	13
36	The relative risk of second primary cancers in Austria's western states: a retrospective cohort study. BMC Cancer, 2017, 17, 699.	2.6	12

NICOLE CONCIN

#	Article	IF	CITATIONS
37	Morphology and tumourâ€infiltrating lymphocytes in highâ€stage, highâ€grade serous ovarian carcinoma correlated with longâ€ŧerm survival. Histopathology, 2018, 73, 1002-1012.	2.9	12
38	γ-Glutamyltransferase and Breast Cancer Risk Beyond Alcohol Consumption and Other Life Style Factors – A Pooled Cohort Analysis. PLoS ONE, 2016, 11, e0149122.	2.5	11
39	Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients– A study of the OVCAD consortium. Gynecologic Oncology, 2018, 149, 371-380.	1.4	11
40	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium. Cancers, 2021, 13, 2613.	3.7	10
41	L1CAM in the Early Enteric and Urogenital System. Journal of Histochemistry and Cytochemistry, 2017, 65, 21-32.	2.5	9
42	Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis. International Journal of Gynecological Cancer, 2021, 31, 713-720.	2.5	7
43	The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer – A Retrospective Study. PLoS ONE, 2017, 12, e0169272.	2.5	7
44	Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer. International Journal of Gynecological Cancer, 2021, 31, 824-828.	2.5	6
45	Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer Journal of Clinical Oncology, 2018, 36, 5567-5567.	1.6	5
46	ABO blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer $\hat{a} \in \hat{a}$ retrospective multi-centre study. BMC Cancer, 2018, 18, 447.	2.6	4
47	Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium. Anticancer Research, 2016, 36, 1015-22.	1.1	4
48	Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study. Cancers, 2022, 14, 1780.	3.7	4
49	European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners – a new Model D for drug and medical device development. International Journal of Gynecological Cancer, 2020, 30, 730-734.	2.5	3
50	Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer. Cancers, 2020, 12, 2519.	3.7	3
51	BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer. Genes, 2021, 12, 969.	2.4	3
52	Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium. Cancers, 2021, 13, 5865.	3.7	3
53	Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with) Tj ETC Gynecological Cancer, 2021, 31, ijgc-2021-002668.	2q1 1 0.784 2.5	1314 rgBT /O 2
54	Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCTO4042116; ENGOT-GYN3/AGO/LIO) Journal of Clinical Oncology, 2022, 40, 5517-5517.	1.6	2

NICOLE CONCIN

#	Article	IF	CITATIONS
55	Primary chemotherapy and maintenance therapy in epithelial ovarian cancer. Memo - Magazine of European Medical Oncology, 2008, 1, 99-102.	0.5	1
56	Response to: Correspondence on "ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors" by Thomassin-Nagarra et al. International Journal of Gynecological Cancer, 2021, 31, 1396-1397.	2.5	1
57	Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer lournal of Clinical Oncology, 2016. 34. e17038-e17038.	1.6	1
58	Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data Journal of Clinical Oncology, 2012, 30, 5071-5071.	1.6	1
59	Implementing clinical practice guidelines: time to assess it. ESMO Open, 2020, 5, e001130.	4.5	0
60	Nomogram prediction for overall survival of patients diagnosed with cervical cancer Journal of Clinical Oncology, 2012, 30, 5111-5111.	1.6	0
61	The role of gamma-glutamyltransferase in malignant transformation and prognosis of ovarian cancer Journal of Clinical Oncology, 2013, 31, e16524-e16524.	1.6	Ο
62	Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer Journal of Clinical Oncology, 2015, 33, 5578-5578.	1.6	0
63	Clinical characterization of long term survivors (LTS) in ovarian cancer (OC): Results of a propensity score matched (PSM) analysis of the international prospective tumor bank for ovarian cancer (TOC) Tj ETQq1 1 C).7 &4 314 ı	rg &T /Overloo
64	EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/-) Tj ETQq0 0 C platinum-sensitive ovarian cancer patients Journal of Clinical Oncology, 2019, 37, TPS5605-TPS5605.) rgBT /Ov 1.6	erlock 10 Tf
65	Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation. International Journal of Gynecological Cancer, 2022, 32, 468-473.	2.5	0